Skip to content
naulon
Get started

Not checked for notices yet.

Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response

Xiang-Xu Wang, Li-Hong Wu, Qiong-Yi Dou and 6 more

Frontiers in Molecular Biosciences · 2022

doi:10.3389/fmolb.2022.1034928

References 54

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  3. 3.
    pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels · 2014
    No notice
  4. 4.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  5. 5.
    RCircos: an R package for Circos 2D track plots · 2013
    No notice
  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.
    GSVA: gene set variation analysis for microarray and RNA-Seq data · 2013
    No notice
  8. 8.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  9. 9.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  10. 10.
    Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression · 2016
    Corrected
  11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.
    Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer · 2018
    No notice
  17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.
    Immune checkpoint therapy in liver cancer · 2018
    No notice
  20. 20.
    Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA) · 2018
    No notice
  21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  24. 24.
    Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer · 2018
    No notice
  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  29. 29.
    Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades · 2019
    Corrected
  30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  34. 34.
    Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma · 2019
    Corrected
  35. 35.
    Functions of N6-methyladenosine and its role in cancer · 2019
    No notice
  36. 36.
    Metabolism‐associated molecular classification of hepatocellular carcinoma · 2020
    No notice
  37. 37.
    m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer · 2020
    No notice
  38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

All 54 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.